Abstract: A bone fusion method, system and device for insertion between bones that are to be fused together and/or in place of one or more of the bones, such as, for example, the vertebrae of a spinal column. The bone fusion device comprises one or more extendable tabs having a central rib. The bone fusion device includes one or more support channels configured to receive an insertion instrument that is then secured to the bone fusion device via a coupling mechanism. As a result, the coupled device is able to be securely positioned between vertebrae using the insertion instrument with minimal risk of slippage.

Abstract: Pharmaceutical compounds have anti-inflammatory activity and, in some aspects, may function as metalloenzyme inhibitors for the beneficial regulation of metalloproteins. A pharmaceutical composition may include a therapeutically effective amount of the compound(s) and a pharmaceutically acceptable vehicle. The pharmaceutical compositions may be useful for treating a disorder associated with chronic inflammation and/or metalloenzyme misregulation, including hemochromatosis, cancers such as breast cancer, or neurodegenerative diseases such as Alzheimer's disease.

Abstract: A system for dispensing ingredients includes a cabinet and a conveyor disposed beneath the cabinet. The conveyor includes a staging region and a dispensing region in communication with an interior of the cabinet through a dispenser opening. One or more containers are removably disposed within the cabinet, and each of the one or more containers has an outlet disposed above the dispenser opening and includes an ejector operable to dispense one of the ingredients through the outlet. One or more bins are removably received within the conveyor. The bins are operable to be moved by the conveyor between a first position in the staging region and a second position in the dispensing region. Within the dispensing region, the conveyor is configured to move the bins between dispensing positions beneath respective ones of the containers.

Abstract: A system has fiber amplifiers that amplify a seed signal into a high power signal. Control circuity drives the fiber amplifiers. An auxiliary broad-linewidth signal can be selectively introduced to mitigate the onset of Stimulated Brillouin Scattering (SBS) when the primary input seed source does not meet the requirements of power and/or linewidth. To determine whether to mitigate SBS, an input photodiode can detect the seed signal, and the control circuity can detect an operational parameter associated with a detected signal indicative of an onset of SBS on the optical path. In response to the detection, the control circuitry introduces an auxiliary broad-linewidth signal from a broad-linewidth source, which can mitigate the onset of SBS on the optical path.

Abstract: A processing system for processing a flexographic printing plate can include a processing path for processing the flexographic printing plate. A hollow tube can be positioned to be extended across the processing path. A pressurized processing liquid supply system is provided. A plurality of pressure-compensating emitters are coupled to the hollow tube Each pressure-compensating emitter can include a casing having a fluidic flow path that is fluidly coupled with the hollow tube and having an outlet. Also, each emitter can include a resilient planar member in the casing and positioned to form at least one resilient surface of the fluidic flow path. Each pressure-compensating emitter is configured to control flow rate of the pressurized processing liquid to produce processing liquid drips from the outlet. The resilient planar member can be positioned to provide a variable outlet cross-sectional profile to the outlet in response to pressure inside the casing.

Abstract: Compositions based on low toxicity solvents, in particular coating formulations, having reduced viscosity are disclosed. The compositions contain polyamideimide polymers having well-defined molecular weight distribution.

Abstract: Systems and methods for neuronavigation in accordance with embodiments of the invention are illustrated. Targeting systems and methods as described herein can generate personalized stimulation targets for the treatment of mental conditions. In many embodiments, direct stimulation of a personalized the stimulation target indirectly impacts a brain structure that is more difficult to reach via the stimulation modality. In various embodiments, the mental condition is major depressive disorder. In a number of embodiments, the mental condition is suicidal ideation.

Abstract: Antibacterial compounds are shown and described. In one aspect, a pharmaceutical composition includes a therapeutically effective amount of an antibacterial compound and a pharmaceutically acceptable vehicle therefor. In another aspect, a method of treating a bacterial infection involves administering the pharmaceutical composition to an individual in need thereof.

Abstract: Systems and methods for treatment verification and re-treatment with iboga alkaloids in accordance with embodiments of the invention are illustrated. One embodiment includes obtaining a first arterial spin labeling (ASL) scan of a patient's brain pre-treatment with an iboga-alkaloid for a neuropsychiatric condition, obtaining a second ASL scan of the patient's brain post-treatment, measuring changes in regional cerebral blood flow (rCBF) in a left orbitofrontal cortex, left insula, right cingulate cortex, and left putamen of the patient's brain based on the first ASL scan and the second ASL scan, determining that the treatment succeeded when either (i) rCBF increased by at least 0.1 in the left orbitofrontal cortex, or (ii) rCBF increased by any amount in the left orbitofrontal cortex and in at least two of the left insula, right cingulate cortex, and left putamen, and determining that the treatment failed when it is not determined that the treatment succeeded.

Abstract: Pharmaceutical compounds have anti-inflammatory activity. A pharmaceutical composition may include a therapeutically effective amount of the compound(s) and a pharmaceutically acceptable vehicle. A method of treating a disorder associated with chronic inflammation involves administering the pharmaceutical composition to an individual in need thereof.

Abstract: In one aspect, an artificial sweetener compound is disclosed. In another aspect, a sweetened composition includes the sweetener compound. In some aspects, the sweetened composition is combined with a product such as a food product, beverage product, or a pharmaceutical product.

Abstract: Pharmaceutical compounds having anticancer activity are disclosed. A pharmaceutical composition may include a therapeutically effective amount of the compound(s) and a pharmaceutically acceptable vehicle. A method of treating a cancer or other disorders involves administering the pharmaceutical composition to an individual in need thereof.

Abstract: Pharmaceutical compounds are described for treating hair loss, promoting hair growth, and/or improving the appearance of hair. In one aspect, a method of increasing hair growth includes administering to an individual in need thereof a pharmaceutical composition containing a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable vehicle therefor. In another aspect, a method of improving the appearance of hair includes administering to an individual in need thereof a pharmaceutical composition containing a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable vehicle therefor.

Abstract: A wire grid polarizer (WGP) can include an array of support-ribs on a substrate. Sides of the support-ribs can be inclined to one side. A wire can be applied on an upper-side and distal end of each support-rib, each wire being separate from wires on adjacent support-ribs. The WGP can be made with reduced or no etching.

Abstract: Compounds disclosed herein may exhibit antibacterial and anti-inflammatory properties. Pharmaceutical compositions containing the compound(s) may be used to treat bacterial infections, such as urinary tract infections, and/or disorders associated with chronic inflammation.

Abstract: A fiber-based optical amplifier is formed to exhibit a reflective architecture in a particular configuration where a single pump source is shared among several individual reflective amplifier elements. A passive, non-variable power splitter is used to direct sub-beams of sufficient power into the rare-earth doped fiber contained within individual amplifiers. Since the reflective architecture results in an optical signal passing through the doped fiber coil (gain medium) twice, a lower pump power (compared to a conventional single-pass structure) may be used to obtain the same target output power level and the single pump source is considered as sufficient to provide enough output power to pass through a power splitting arrangement and deliver enough pump power to provide amplification of a propagating optical signal in each of the individual amplifiers.

Abstract: Pharmaceutical compounds have anti-inflammatory activity. A pharmaceutical composition may include a therapeutically effective amount of the compound(s) and a pharmaceutically acceptable vehicle. A method of treating a disorder associated with chronic inflammation, such as arthritis, involves administering the pharmaceutical composition to an individual in need thereof.

Abstract: A watercraft includes: a deck; and a first pontoon coupled with the deck, the first pontoon including: a first body; a first marine propulsion device coupled with the first body; and a first electric motor operably coupled with the first marine propulsion device and disposed within the first body.

Abstract: Compounds disclosed herein may be useful for treating a glucose and lipid metabolism disorders, such as hyperlipidemia, diabetes, fatty liver, obesity, and arteriosclerotic cardiovascular and cerebrovascular diseases. In some aspects, a pharmaceutical composition contains a glucose and lipid metabolism regulating agent(s) and a pharmaceutically acceptable vehicle therefor.

Abstract: An oral irrigator handle including a housing and a first fitting, the first fitting including a first fitting inlet in fluid communication with a handle inlet in fluid communication with a fluid source and a first fitting outlet in fluid communication with the first fitting inlet. The handle includes a seal positioned around the first fitting and between the first fitting inlet and the first fitting outlet. A second fitting includes a second fitting inlet in fluid communication with the first fitting outlet and a second fitting outlet in fluid communication with the second fitting inlet. A bottom portion of the second fitting seats on a portion of the first fitting so that the seal engages an interior surface of the second fitting, a flow passage is coupled to the second fitting and in fluid communication with the second fitting outlet.